Ikarian Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Ikarian Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,519	Closed	-$552K	–	185
2025 Q1	$552K	Sell	12,519 -25,000	-67%	-$1.15M	0.07%	113
2024 Q4	$1.36M	Buy	+37,519	New	+$1.31M	0.18%	96
2023 Q4	–	Sell	-178,360	Closed	-$4.12M	–	179
2023 Q3	$4.12M	Buy	+178,360	New	+$4.88M	0.5%	53

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Ikarian Capital's SWTX Position: Q2 2025 in Review

Ikarian Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 12,519 shares — an estimated $552K sold.

Ikarian Capital first reported a position in SWTX in Q3 2023 and held it in 3 quarters. The position peaked at $4.12M in Q3 2023. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Ikarian Capital reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 12,519 SpringWorks Therapeutics shares in Q2 2025, an estimated $552K.
Ikarian Capital first reported a position in SpringWorks Therapeutics in Q3 2023 and held it in 3 quarters.
Ikarian Capital's SpringWorks Therapeutics position peaked at $4.12M in Q3 2023.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.